Medcura, Inc.

Medcura, Inc. (formerly gel-e, Inc.) is a surgical technology company developing a proprietary hemostasis portfolio based on natural, hydrophobically modified biomaterials designed to control minimal, mild, and moderate surgical bleeding. The company's lead product, LifeGel™, is a non-swelling flowable hemostatic gel engineered specifically for confined surgical spaces, particularly spine surgery, where swelling-related complications such as nerve injury or paralysis can occur with conventional hemostatic agents. LifeGel has received FDA Breakthrough Device Designation for surgical procedures where swelling cannot be tolerated. The company's products achieve hemostasis through mechanical means via mucoadhesion, positioning them as lower-cost alternatives to existing hemostatic solutions while addressing unmet clinical needs in the $2.5B hemostasis market. Medcura targets cost-effective bleeding management for hospitals, surgical centers, and payers, with a focus on strategic purchasing opportunities and provider savings. The company operates with scientific, engineering, and clinical expertise, including an advisory board of world-class spinal surgeons. Currently, LifeGel and its application components remain in active development and have not yet received FDA clearance or approval for commercial use.